The reduced spleen weights and prolonged survival of PDX-1 mice treated with high doses of TSLP indicated that TSLP may reduce the number of leukemia cells (tumor burden) in the xenograft mice and prolong the survival of the mice. This evidence concerns the gene TSLP and neoplasm.